Mitacs Accelerate supports process development for 3C Therapeutics’ DAC research
On June 22, 2026, Mitacs Accelerate awarded support for a research collaboration between 3C Therapeutics and Professor David Perrin’s laboratory at the University of British Columbia.
The project focuses on process development and scale-up of protein degrader prototypes for evaluation as degrader-antibody conjugates, while supporting research training through a Mitacs internship.